used vascular endothelial growth factor (VEGF) and its receptor type II (VEGFR2) as a target for active targeting of cisdiamminedinatratoplatinum‐loaded liposomes toward glioma cells.[163] Antibodies against VEGF and VEGFR2 were conjugated to the liposomal surface, and revealed prolonged blood circulation in glioma C6‐bearing rats, as compared with free drug. This evidence concerns the gene VEGFA and central nervous system cancer.